<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294385</url>
  </required_header>
  <id_info>
    <org_study_id>CECOG/BC 1.3.002</org_study_id>
    <nct_id>NCT00294385</nct_id>
  </id_info>
  <brief_title>Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine</brief_title>
  <official_title>A Randomized Phase III Study Comparing Concomitant Docetaxel Plus Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the Time To Disease Progression (TTDP) between those
      patients with unresectable, locally recurrent or metastatic breast cancer who are treated
      with concomitant Docetaxel plus Gemcitabine to those patients treated with sequential therapy
      of Docetaxel followed by Gemcitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, multicenter, two-armed Phase III study

      Patients will be randomized to either of the following two arms:

      Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1
      and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine),
      repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8
      cycles will be administered.

      Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22,
      followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will
      be given. Both drugs will be administered in a 3-week schedule.

      Bimonthly follow-up for patients without confirmed disease progression until progression of
      disease. Long-term follow-up for patients with confirmed disease progression will be done in
      4 intervals.

      For therapy control frequent blood chemistry and hematology, physical examination, weight
      control, potential adverse events and imaging procedures (CT, X-ray, MRI, Bone scan) am
      foreseen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare the Time To Disease Progression between those patients with unresectable, locally recurrent or metastatic breast cancer who are treated with concomitant Docetaxel plus Gemcitabine to those patients treated with sequential therapy of Doc</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize changes in performance status, patient-reported pain, and disease-related symptoms in each arm</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the nature of the toxicities experienced in each arm</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Gemcitabine, Docetaxel</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Docetaxel</intervention_name>
    <description>Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.</description>
    <arm_group_label>Gemcitabine, Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologic or cytologic diagnosis of breast cancer with evidence of
             unresectable, locally recurrent, or metastatic disease.

          -  Females, 18 to 75 years of age

          -  pre-treated with ONE anthracyclines containing chemotherapy either in
             neoadjuvant/adjuvant or 1st line metastatic setting will be enrolled into the study

          -  Patients with clinically measurable lesions will be enrolled in this study.
             Measurability is determined according to RECIST criteria

          -  Performance status of 70 or higher on the Karnofsky Performance Scale

          -  Adequate bone marrow reserve

          -  Adequate liver function

          -  Adequate renal function

          -  Informed consent form patient or guardian

          -  Childbearing potential either terminated by surgery, radiation, or menopause, use of
             an approved contraceptive method

        Exclusion Criteria:

          -  Active infection (at the discretion of the investigator).

          -  Known or suspected brain metastases requiring steroid or radiation treatment.

          -  Pregnancy (recent negative urine pregnancy test for pre-menopausal patients mandatory)

          -  Breast-feeding

          -  Serious concomitant systemic disorders incompatible with the study (at the discretion
             of the investigator).

          -  Second primary malignancy (except in situ carcinoma of the cervix or adequately
             treated basal cell carcinoma of the skin).

          -  Bone metastases, pleural effusion, or ascites as the only site of disease.

          -  Bone marrow transplantation or autologous stern cell infusion following high-dose
             chemotherapy for adjuvant or metastatic disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Wiltschke, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ. Klinik f. Innere Medizin I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2. Med. Abteilung - LKH-Steyr</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch KrankenhausHÃ¤matologisch-Onkologisches Zentrum</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intere IV Krankenhaus Wels</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALO National Oncology Center</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALO National Oncology Center</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN U sv. Anny</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Ceske Budejovice</name>
      <address>
        <city>Ceske</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Bulovka</name>
      <address>
        <city>Prague</city>
        <zip>186 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University Prague, Dep of Oncology</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center, Oncol. Dep</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center, Div of Oncology</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Sheba&quot; Medical Center, Dep of Oncology</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut, Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rizk Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii CMuJ</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nomocnica Sv. Alzbety, Narodny Onkologicky Ustav</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Israel</country>
    <country>Lebanon</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2006</study_first_submitted>
  <study_first_submitted_qc>February 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Thomas Brodowicz</name_title>
    <organization>CECOG</organization>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

